Profil
Gordon J.
Brooks currently works at Dermira, Inc., as Director from 2020, ARMO BioSciences, Inc., as Director from 2018, and Sigilon Therapeutics, Inc., as Director from 2023.
Postes actifs de Gordon Brooks
| Sociétés | Poste | Début |
|---|---|---|
| ARMO BIOSCIENCES INC | Directeur/Membre du Conseil | 21/06/2018 |
| DERMIRA, INC. | Directeur/Membre du Conseil | 20/02/2020 |
| SIGILON THERAPEUTICS, INC. | Directeur/Membre du Conseil | 11/08/2023 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| SIGILON THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
ARMO BioSciences, Inc.
 ARMO BioSciences, Inc. Pharmaceuticals: MajorHealth Technology ARMO BioSciences, Inc. develops immunotherapy for the treatment of cancer, cardiovascular diseases, fibrosis, and inflammation. Its lead product candidate is AM0010 (pegilodecaki). The company was founded by Peter Van Vlasselaer, Martin Oft, and John B. Mumm on June 23, 2010 and is headquartered in Redwood, CA. | Health Technology |
Dermira, Inc.
 Dermira, Inc. Pharmaceuticals: MajorHealth Technology Dermira, Inc. is a biopharmaceutical company. It engages in the provision of therapies for chronic skin conditions. The company was founded by Thomas G. Wiggans, Eugene Andrew Bauer, Luis C. Peña, and Christopher M. Griffith on August 18, 2010 and is headquartered in Indianapolis, IN. | Health Technology |
